Oct. 29 - With supplies tight, US buys up Lilly COVID-19 drug | Novartis bets on a scalable antiviral

Novartis, Molecular Partners partner to develop a scalable COVID-19 drug; Sanofi, GSK pledge 200M doses to an international coronavirus vaccine alliance View online | Signup | Forward

Manufacturing weekly Oct.​ 29,​ 2020 | This week's manufacturing news and insights for biopharma leaders   BROUGHT TO YOU BY — Pall Biotech New Webinar Series: Vaccine Production Attendees will get a critical look at the vaccine industry today, its globalization and how the cost of a vaccine is assessed. Register now.   Note from the editor Next week, you will receive this newsletter under a new name. On Nov. 5, Manufacturing Weekly will become Gene Therapy Weekly. More than the name will change: We will use Gene Therapy Weekly to report deeply on the fast-emerging field of genetic medicine, from gene therapy to CRISPR gene editing and engineered cell therapy. Manufacturing is crucial for gene therapies, and we'll continue to cover how drugmakers design and build the complex treatments, as you've seen included here previously. But beginning Nov. 5, this newsletter will report exclusively on gene therapies and their development. We're very excited to spend more time covering a space that's on the industry's cutting edge, and we think you'll enjoy our coverage, too. We'll still report on major manufacturing news that doesn't involve gene therapy in our Daily Dive, which you can sign up for here. Next Thursday, you'll automatically receive the first issue of Gene Therapy Weekly. If you're not interested in reading about gene therapy, you can update your subscription. Please let us know if you have any questions, and we hope to count you as a reader for years to come! Ned Pagliarulo Senior Editor, BioPharma Dive E-mail | Twitter US to pay Lilly $375M for supply of COVID-19 drug Lilly has asked the FDA for emergency approval of the antibody-based treatment, but scaling up production will take time.  Novartis, Molecular Partners partner to develop a scalable COVID-19 drug The two Swiss firms will develop protein drugs that are meant to have similar effects as coronavirus antibodies, but would be easier to mass produce. Sponsored Content by SAP Regulatory-driven material control with SAP Learn about material segmentation, a unique approach for characteristics-based planning and execution. Sanofi, GSK pledge 200M doses to an international coronavirus vaccine alliance The two drugmakers are aiding an international effort to ensure low- and middle-income countries can get access to successful coronavirus shots.  Read more news The Impact of Real-World Evidence The FDA recently committed to advancing the use of real-world data in order to support the development of more effective treatments, including four oncology drugs from Pfizer. Learn More From Our Library Trendline Inside the Rapidly Changing World of Gene Therapy View all resources What We're Reading Bloomberg Vaccine Makers Can Skip U.S. Inspections FiercePharma Catalent continues big push into cell and gene therapies with Belgian facility buyout Reuters FDA delays decision on Spectrum Pharma's drug candidate due to travel curbs Supply Chain Dive Supply chain cities on the rise Suggest a story we should read Upcoming Event Optimizing IRT Design and Management to Future Proof Your Trial Nov. 17, 2020 - Nov. 17, 2020 | Webinar 11am ET Company Announcements Press releases from companies in your industry. RCPE awarded two FDA contracts for next-generation pharma technology Press release from RCPE - Research Center Pharmaceutical Engineering GmbH Lumis International GmbH spins off its consulting business to Lumis Life Science Consulting GmbH Press release from Lumis International GmbH Saama Launches Active Safety Analytics for Pharma (ASAP), Co-built with Gilead to Transform Safety Surveillance Press release from Saama Technologies BioIVT to Host Emerging Technologies in Diagnostics Symposium Press release from BioIVT Post a press release Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Manufacturing Weekly with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Manufacturing Weekly. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | Facebook | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Manufacturing Weekly is a product of Industry Dive, Inc.. 1575​ Eye St NW, 4th Floor, Washington,​ DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip